FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE ...
DUBLIN--(BUSINESS WIRE)-- ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites ...
The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory biomaterial-based cancer vaccine, in a cohort of 21 patients with stage 4 metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results